Oorja Bio, backed by Westlake, is planning a mid-stage study for an idiopathic pulmonary fibrosis (IPF) candidate, according to a venture-focused update. The report frames the move as a step to advance the program beyond early proof-of-concept while positioning it for later-stage clinical differentiation in a high-risk therapeutic area. The development aligns with the broader expectation that fibrotic disease programs need clean, interpretable endpoints to compete for partnership capital and eventual commercialization support. Investors will likely track which trial design and patient subgroups Oorja selects as the company moves into its next inflection point. Details on trial size, endpoints, and timelines were not provided in the headline brief.